Ximelagatran Compared with Warfarain for prevention of thromboembolism in patients with nonvalvular atiral fibrillaton: Rationale. Objectives and design of a pair of clinical trials and baseline patient characteristics (SPORTIF III and V).
Background Ximelagatran is a novel, oral direct thrombin inhibitor under investigation as an alternative to warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation (AF). Two long-term studies in patients with AF and at least one additional risk factor for stroke are underway to compare the safety and efficacy of fixed-dose ximelagatran (36 mg bid) without coagu